Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vascular closure device

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Vascular closure device. Displaying page 1 of 1.
    EudraCT Number: 2018-003621-28 Sponsor Protocol Number: 5072018 Start Date*: 2019-07-23
    Sponsor Name:IUCPQ
    Full Title: Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.
    Medical condition: Device thrombosis at 2 months and 12 months after left atrial appendage closure (LAAC) Ischemic events (stroke, TIA) at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Bleeding events at 2-month an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10047065 - Vascular disorders 10005103 Bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000110-19 Sponsor Protocol Number: P060406 Start Date*: 2012-01-10
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Closure of patent foramen ovale or anticoagulants versus antiplatelet therapy to prevent stroke recurrence
    Medical condition: The study compares different strategies for secondary stroke (or retinal ischaemia) prevention in patients with patent foramen ovale. The three treatment arms comprise: 1. Endovascular patent f...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10036654 Prevention LLT
    19.0 100000004850 10016982 Foramen ovale patent LLT
    19.0 100000004852 10042244 Stroke LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000058-21 Sponsor Protocol Number: CLOSURE-AF-DZHK16 Start Date*: 2018-03-01
    Sponsor Name:Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
    Full Title: Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial
    Medical condition: Atrial Fibrillation with high risk of stroke and bleeding
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003415-22 Sponsor Protocol Number: AP-W-CLI-2018-8 Start Date*: 2019-03-22
    Sponsor Name:Aurealis Oy
    Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers
    Medical condition: Diabetic foot ulcers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002467-26 Sponsor Protocol Number: 480-SFA2013-001 Start Date*: 2013-08-30
    Sponsor Name:480 Biomedical, Inc.
    Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions
    Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001975-30 Sponsor Protocol Number: BAY59-7939/17938 Start Date*: 2016-01-12
    Sponsor Name:Bayer AG
    Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ...
    Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10002916 Aortic valve replacement PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000934-31 Sponsor Protocol Number: INN-TOP-005 Start Date*: 2015-07-10
    Sponsor Name:Innocoll Pharmaceuticals Limited
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Pa...
    Medical condition: Diabetic Patients with an Infected Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10021784 Infected skin ulcer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) SK (Completed) NL (Completed) GB (Completed) PL (Completed) HU (Completed) DK (Completed) LV (Completed) LT (Completed) EE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002235-25 Sponsor Protocol Number: A1481131 Start Date*: 2006-12-14
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.0 10064911 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) SK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-003952-29 Sponsor Protocol Number: BAY63-2521/15681 Start Date*: 2015-08-25
    Sponsor Name:Bayer AG
    Full Title: Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (...
    Medical condition: Hypertension, Pulmonary
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) IT (Trial now transitioned) GB (Completed) DE (Trial now transitioned) ES (Prematurely Ended) PL (Completed) Outside EU/EEA BE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004207-39 Sponsor Protocol Number: AGO-OVAR2.34 Start Date*: 2021-06-07
    Sponsor Name:AGO Research GmbH
    Full Title: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC ...
    Medical condition: This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-ba...
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003309-88 Sponsor Protocol Number: ROR-PH-302 Start Date*: 2020-06-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He...
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:12:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA